http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-29T06:10:47.611Z

http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

when oral therapy is not feasible and the strength dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition the intravenous or intramuscular use of solu medrol sterile powder is indicated as follows allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma atopic dermatitis contact dermatitis drug hypersensitivity reactions perennial or seasonal allergic rhinitis serum sickness transfusion reactions dermatologic diseases bullous dermatitis herpetiformis exfoliative erythroderma mycosis fungoides pemphigus severe erythema multiforme stevens johnson syndrome endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis gastrointestinal diseases to tide the patient over a critical period of the disease in regional enteritis systemic therapy and ulcerative colitis hematologic disorders acquired autoimmune hemolytic anemia congenital erythroid hypoplastic anemia diamond blackfan anemia idiopathic thrombocytopenic purpura in adults intravenous administration only intramuscular administration is contraindicated pure red cell aplasia selected cases of secondary thrombocytopenia miscellaneous trichinosis with neurologic or myocardial involvement tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy neoplastic diseases for the palliative management of leukemias and lymphomas nervous system acute exacerbations of multiple sclerosis cerebral edema associated with primary or metastatic brain tumor or craniotomy ophthalmic diseases sympathetic ophthalmia uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids renal diseases to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus respiratory diseases berylliosis fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy idiopathic eosinophilic pneumonias symptomatic sarcoidosis rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in acute gouty arthritis acute rheumatic carditis ankylosing spondylitis psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy for the treatment of dermatomyositis temporal arteritis polymyositis and systemic lupus erythematosus

Leoni Bücken

2021-06-29T06:10:47.611Z

http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_1339 DOID_1339

Leoni Bücken

2021-06-29T06:10:47.611Z

http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-29T06:10:47.611Z

http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB00959 drugbank:DB00959

Leoni Bücken

2021-06-29T06:10:47.611Z

http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-29T06:10:47.611Z

http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-29T06:10:47.611Z

http://purl.org/np/RAelo3UZ9x... RAelo3UZ9x

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://schema.org/TreatmentIndication TreatmentIndication

Leoni Bücken

2021-06-29T06:10:47.611Z